| |
| |
Samuel Z. Goldhaber, MD
|
|
Professor of Medicine
Harvard Medical School
Staff Cardiologist, Director of the Anticoagulation Service
Director of the Venous Thromboembolism Research Group
Brigham and Women’s Hospital
Boston, Massachusetts Samuel Z. Goldhaber is Professor of Medicine at Harvard Medical School. He is a staff cardiologist at Brigham and Women’s Hospital (BWH), in Boston, where he practices general cardiology, attends to patients in the Coronary Care Unit, and oversees the BWH Thromboembolism Consultation Service. Dr Goldhaber is Founder and Director of the Anticoagulation Service at BWH, which cares for about 1,500 patients. He is also Director of the BWH Venous Thromboembolism Research Group. Dr Goldhaber received his AB from Harvard College and his MD from Harvard Medical School. He completed his postgraduate training in internal and cardiovascular medicine at the Peter Bent Brigham Hospital (now BWH).
Dr Goldhaber is a member of the Program Organizing Committee for the International Society on Thrombosis and Haemostasis. In 2002, he was appointed to the organization’s Council on Thrombosis and the World Federation of Cardiology. In 2004, he was named the Eberhard Mammen Lecturer in Clinical Coagulation Science.
Dr Goldhaber’s clinical interests focus on venous and arterial thromboembolism, atrial fibrillation, acute coronary syndromes, anticoagulation, and thrombolytic therapy. He has been the Principal Investigator for multiple DVT and pulmonary embolism (PE) treatment trials, including 5 multicenter PE thrombolysis trials. He has lectured widely and published extensively on these topics. He wrote a perspective on the indications for PE thrombolysis that appeared in the October 10, 2002 New England Journal of Medicine. He also coauthored a two-part review of pulmonary embolism that was published in Circulation in December, 2003. On April 17, 2004 he published a Review Article about PE in Lancet. He was the principal discussant of a May 27, 2004 New England Journal of Medicine Clinicopathological Case in which a 42-year-old woman suffered cardiac arrest several weeks after an ankle fracture.
Dr Goldhaber was the Co-Principal Investigator of DVT FREE, the largest prospective registry of DVT. He was also Clinical Director of the recently completed National Institutes of Health–sponsored trial that studied the optimal duration and intensity of anticoagulation among patients with idiopathic VTE. In addition, he served as Co-Principal Investigator of the largest trial of pharmacological prophylaxis in hospitalized patients with medical illness (published in the August 17, 2004 issue of Circulation). Dr Goldhaber co-directs two Harvard Medical School Continuing Medical Education courses: a 5-day course reviewing all aspects of cardiovascular medicine and a 2-day course reviewing thrombosis and thromboembolism. He is a member of the editorial boards of several journals, including the American Journal of Cardiology. |